University of Oulu

von Hofsten S, Langer MK, Korelin K, Magnussen S, Ausbacher D, Anderssen T, Salo T, Strøm MB, Bayer A, Al-Samadi A and Berge G (2023), Amphipathic barbiturates as marine product mimics with cytolytic and immunogenic effects on head and neck squamous cell carcinoma cell lines. Front. Pharmacol. 14:1141669. doi: 10.3389/fphar.2023.1141669

Amphipathic barbiturates as marine product mimics with cytolytic and immunogenic effects on head and neck squamous cell carcinoma cell lines

Saved in:
Author: von Hofsten, Susannah1; Langer, Manuel K.2; Korelin, Katja3,4;
Organizations: 1Department of Medical Biology, Faculty of Health Sciences, UiT—The Arctic University of Norway, Tromsø, Norway
2Department of Chemistry, Faculty of Science and Technology, UiT—The Arctic University of Norway, Tromsø, Norway
3Department of Oral and Maxillofacial Diseases, University of Helsinki, Helsinki, Finland
4Translational Immunology Research Program (TRIMM), University of Helsinki, Helsinki, Finland
5Department of Pharmacy, Faculty of Health Sciences, UiT—The Arctic University of Norway, Tromsø, Norway
Format: article
Version: published version
Access: open
Online Access: PDF Full Text (PDF, 4.3 MB)
Persistent link: http://urn.fi/urn:nbn:fi-fe2023070584069
Language: English
Published: Frontiers Media, 2023
Publish Date: 2023-07-05
Description:

Abstract

The incidence of head and neck squamous cell carcinoma (HNSCC) is increasing and the conventional treatments for this form of cancer can be tough. Despite the success of existing immunotherapies in some HNSCC patients, many do not respond to this type of treatment. Thus, the development of novel anti-cancer therapies should be prioritized. In the current study, the anticancer activity of a panel of novel compounds, herein termed marine product mimics (MPMs), against HNSCC cell lines is explored. The previously reported compound MPM-1, which is structurally related to the novel MPMs, was shown to have promising effects on the HNSCC cell line HSC-3. The results from the current study indicate that the novel MPMs are more potent than MPM-1 but cause a similar type of cell death. The results indicated that the MPMs must cross through the cell membrane to exert their action and that they are lysosomotropic. Further experiments showed that some of the MPMs could induce phosphorylation of eukaryotic initiation factor 2α (eIF2α) in HSC-3 and UT-SCC-24A cells, which indicates that they can activate the integrated stress response that is strongly associated with immunogenic cell death. Cell surface expression of calreticulin and release of HMGB1 and ATP, which are all hallmarks of immunogenic cell death, was also demonstrated in HSC-3 and UT-SCC-24A cells treated with MPMs. This suggests that the MPMs are interesting candidates for future HNSCC cancer therapies.

see all

Series: Frontiers in pharmacology
ISSN: 1663-9812
ISSN-E: 1663-9812
ISSN-L: 1663-9812
Volume: 14
Article number: 1141669
DOI: 10.3389/fphar.2023.1141669
OADOI: https://oadoi.org/10.3389/fphar.2023.1141669
Type of Publication: A1 Journal article – refereed
Field of Science: 313 Dentistry
Subjects:
Funding: This work was supported by grants from the Jane and Aatos Erkko Foundation, the Finnish Dental Society Apollonia, and the AKM fund from UiT—The Arctic University of Norway. SH received a travel grant from UiT—The Arctic University of Norway to travel to Helsinki and perform some of the presented work. The publication charges for this article have been funded by a grant from the publication fund of UiT—The Arctic University of Norway.
Copyright information: © 2023 von Hofsten, Langer, Korelin, Magnussen, Ausbacher, Anderssen, Salo, Strøm, Bayer, Al-Samadi and Berge. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
  https://creativecommons.org/licenses/by/4.0/